Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Appointment of Aaron Wong as CFO of Magle Group

Magle Chemoswed Holding
Download the release

Magle Group is pleased to announce the appointment of Aaron Wong as its new Chief Financial Officer (CFO), effective 7th January 2025.

Aaron brings a wealth of experience in the life sciences sector, having held senior financial leadership positions and earned a reputation for driving growth, operational efficiency, and strategic transformation.

This appointment marks an important milestone in Magle Group’s growth strategy and commitment to internationalisation. Aaron will play a key role in supporting the ongoing integration of PK Chemicals A/S and Amniotics AB into the Magle Group, ensuring financial strength and operational synergy across the organisation.

“Aaron’s extensive experience and forward-thinking approach make him the ideal candidate to help guide Magle Group through its next phase of growth,” said Hans Henrik Lidgard, Chair of Magle Group. “His leadership will be vital as we strengthen our position globally and continue to drive value for our stakeholders.”

Aaron Wong is a Fellow of the Association of Chartered Certified Accountants (FCCA) and brings over a decade of experience in financial management within the life sciences industry.

Contacts


Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us


The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-05 08:50 CET.

Attachments


Appointment of Aaron Wong as CFO of Magle Group

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team